2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119572
    Sodium zirconium cyclosilicate 17141-74-1
    Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K+ in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD).
    Sodium zirconium cyclosilicate
  • HY-123967
    RNF5 inhibitor inh-02 324579-65-9 ≥98.0%
    RNF5 inhibitor inh-02 is a potent inhibitor of E3 ubiquitin ligase RNF5/RMA1. RNF5 inhibitor inh-02 rescues F508del-CFTR function in F508del-CFTR-expressing immortalized cells (CFBE41o⁻, EC50 = 2.6 μM; FRT, EC 50 = 2.2 μM). RNF5 inhibitor inh-02 increases LC3IIB expression and autophagic vacuole number via reducing ATG4B ubiquitylation and promotes cell motility. RNF5 inhibitor inh-02 can be used for the study of cystic fibrosis.
    RNF5 inhibitor inh-02
  • HY-125904
    4-Hydroxyretinoic acid 66592-72-1
    4-Hydroxyretinoic acid (4-HRA) is a derivative of Retinoic acid (HY-14649). 4-Hydroxyretinoic acid is formed via the catalysis of retinol by cytochrome P-450 isoenzymes. 4-Hydroxyretinoic acid also serves as a substrate for UDP-glucuronosyltransferase (s) and recombinant UGT2B7. 4-Hydroxyretinoic acid binds to the nuclear receptor RAR (Retinoic Acid Receptor), activates RAR and RXR-alpha, subsequently regulates gene expression and cell differentiation, and induces cancer cell apoptosis (Apoptosis). 4-Hydroxyretinoic acid also participates in multiple physiological processes such as immunoregulation, neuroprotection and antioxidation.
    4-Hydroxyretinoic acid
  • HY-126066
    (-)-Syringaresinol 6216-81-5 99.93%
    (-)-Syringaresinol is an orally active isomer of syringaresinol (HY-N8307) found in Annona Montana. (-)-Syringaresinol exhibits antioxidant, anti-inflammatory, and anticancer activities. (-)-Syringaresinol can alleviate ulcerative colitis via the PI3K-Akt/MAPK/Wnt signaling pathway. (-)-Syringaresinol inhibits HL-60 cell proliferation by arresting the G1 phase and inducing apoptosis. (-)-Syringaresinol inhibits LPS (HY-D1056)-induced microglial activation by downregulating the NF-κB p65 signaling pathway and its interaction with ERβ, exerting anti-neuroinflammatory effects.
    (-)-Syringaresinol
  • HY-126145
    S1PR1 modulator 1 2328109-05-1 99.52%
    S1PR1 modulator 1 is a selective S1PR1 inhibitor, with a pIC50 of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4.
    S1PR1 modulator 1
  • HY-126154
    L48H37 343307-76-6
    L48H37 is an analog of Curcumin (HY-N0005) with improved chemical stability. L48H37 is a potent and specific myeloid differentiation protein 2 (MD2) inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is used for the research of sepsis or lung injury treatment.
    L48H37
  • HY-126975
    Propargyl-PEG3-acid 1347760-82-0 ≥98.0%
    Propargyl-PEG3-acid is a non-cleavable (3 unit PEG) ADC linker and also a PEG-based PROTAC linker that can be used to synthesis 6-OHDA-PEG3-yne. 6-OHDA-PEG3-yne contains 6-OHDA (HY-B1081, HY-B1081A) and Propargyl-PEG3-acid. Propargyl-PEG3-acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Propargyl-PEG3-acid
  • HY-128113
    AG-09/1 356776-32-4 99.48%
    AG-09/1 is a specific formyl peptide receptor 1 (FPR1) agonist. N-formyl peptide receptors (FPR) are important in host defense.
    AG-09/1
  • HY-128481
    SB24011 1497415-41-4 99.7%
    SB24011 is a STING modulator and a TRIM29-STING protein-protein interaction inhibitor. SB24011 blocks TRIM29-induced K48-linked specific ubiquitination by binding to STING, thereby upregulating intracellular STING protein levels. SB24011 enhances inflammatory cytokine expression and STING-mediated immune responses, and exhibits abscopal antitumor activity that promotes tumor regression and activates T cell infiltration. When combined with STING agonists or anti-PD1 antibodies, SB24011 synergistically enhances antitumor responses. SB24011 is suitable for research related to colon cancer and melanoma.
    SB24011
  • HY-129421
    PA-9 1436004-46-4 99.73%
    PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain.
    PA-9
  • HY-129453
    BOP sodium 1947348-42-6 99.25%
    BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with Kd values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins.
    BOP sodium
  • HY-133159
    Resolvin E2 865532-70-3 98.5%
    Resolvin E2 ((-)-Resolvin E2) is an endogenous lipid mediator produced from eicosapentaenoic acid (EPA) under the catalysis of 5-lipoxygenase (5-LOX), and its production increases in hypoxic environments. Resolvin E2 antagonizes BLT1, partially activates ChemR23, and promotes ubiquitin-proteasome-mediated degradation of COX-2. Resolvin E2 reduces the production of prostaglandin E2, blocks polymorphonuclear leukocyte infiltration, and promotes the resolution of airway inflammation. Resolvin E2 ameliorates lipopolysaccharide (LPS) (HY-D1056)-induced depressive-like behaviors. Resolvin E2 can be used in research related to depression, murine peritonitis, neonatal asthma, and other conditions.
    Resolvin E2
  • HY-134334
    C/EBPα inducer 1 2374285-52-4 99.82%
    C/EBPα inducer 1 (compound 78) is a potent inducer of C/EBPα and myeloid differentiation.
    C/EBPα inducer 1
  • HY-138558
    PAR-2-IN intermediate-1 1690176-75-0 98.92%
    PAR-2-IN intermediate-1 is a drug intermediate that can be used to synthesize inhibitors of the PAR-2 signaling pathway.
    PAR-2-IN intermediate-1
  • HY-139690
    CCG258747 2615910-00-2 98.96%
    CCG258747 is a selective GRK2 inhibitor (IC50 = 18 nM) with high selectivity over GRK1, GRK5, PKA, and ROCK1 (518, 83, > 5500, and > 550-fold, respectively). CCG258747 also blocks the internalization of the µ-opioid receptor (MOR). CCG258747 attenuates IgE mediated anaphylaxis by inhibiting GRK2 and FcεRI signaling pathway but activates mast cells via MRGPRX2 and MRGPRB2. CCG258747 can be used to study diseases related to overexpression of GRK2 (such as heart failure, opioid tolerance).
    CCG258747
  • HY-141582
    Ceramide 3 34354-88-6 98.0%
    Ceramide 3 (N-Stearoyl phytosphingosine) is an orally active major component of intercellular lipids in the stratum corneum of the skin, and belongs to the ceramide family. Ceramide 3 inhibits c-jun and NF-κB activation induced by Histamine (HY-B1204), and suppresses the expression of IL-4 and TNF-α. Ceramide 3 inhibits scratching behavior and vascular permeability in mice, and exhibits antihistamine effects in guinea pig ileum. Ceramide 3 improves skin barrier function, reduces transepidermal water loss, erythema and the number of circulating epidermal cells, and accelerates barrier repair of irritated or dysfunctional skin.
    Ceramide 3
  • HY-144765
    NF-κB-IN-4 3033258-60-2 98.51%
    NF-κB-IN-4 (compound 17) is a potent NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research.
    NF-κB-IN-4
  • HY-145653
    GSK2647544 1380426-95-8 99.50%
    GSK2647544 is an orally available, selective inhibitor of Lp-PLA2. Lipoprotein-associated phospholipase (Lp-PLA2) is a calcium-independent phospholipase A2 with proinflammatory activities that is primarily secreted by monocyte-derived macrophages.
    GSK2647544
  • HY-145919
    hGPR91 antagonist 3 1314796-31-0 99.01%
    hGPR91 antagonist 3 (Compound 5g) is a potent and orally active GPR91 antagonist with IC50s of 35 nM and 135 nM, for human GPR91 and rat GPR91, respectively.
    hGPR91 antagonist 3
  • HY-147817
    Heme Oxygenase-2-IN-1 2994198-37-5 98.82%
    Heme Oxygenase-2-IN-1 (Compound 9) is a potent, selective heme oxygenase-2 (HO-2) inhibitor with IC50 values of 0.9 μM and 14.9 μM against HO-2 and HO-1, respectively.
    Heme Oxygenase-2-IN-1
Cat. No. Product Name / Synonyms Application Reactivity